Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.

Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Biosimilar (Tag) Articles ...

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira®
http://www.prnewswire.com, , 27-Jul-2017
Biosimilars: Imitation Games.
Medline, ACS medicinal chemistry letters [8] 690-693, 27-Jul-2017
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.
Medline, Journal of market access & health policy [5] 1345580, 27-Jul-2017
Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
Medline, Journal of market access & health policy [5] 1307315, 27-Jul-2017
Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.
Medline, World journal of gastroenterology [23] 4473-4479, 27-Jul-2017
Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
https://seekingalpha.com, , 26-Jul-2017
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)
http://www.worldpharmanews.com, , 26-Jul-2017
Pfizer announced positive results from the comparative study for PF-06439535, a potential biosimilar to Avastin
http://www.biosimilarnews.com, , 26-Jul-2017
MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation
ClinicalTrials.gov, , 26-Jul-2017
Samsung Leaps Into Its First U.S. Biosimilars Battle
https://seekingalpha.com, , 25-Jul-2017
Merck announces launch of Renflexis (Remicade biosimilar) in the United States
http://www.biosimilarnews.com, , 25-Jul-2017
World Biosimilar Congress Europe 2017
http://www.biosimilarnews.com, , 25-Jul-2017

  This Weeks Biosimilar (Tag) Articles ...

Merck & Co launches Remicade biosimilar in US, undercutting rivals
http://www.pmlive.com, , 25-Jul-2017
Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
Medline, The AAPS journal, 25-Jul-2017
Molecular and functional analysis of monoclonal antibodies in support of biologics development.
Medline, Protein & cell, 25-Jul-2017
Targeting a $5B brand, Samsung and Merck launch Remicade biosim at 35% discount
http://www.fiercepharma.com, , 24-Jul-2017
Daiichi Sankyo discontinues etanercept biosimilar development in Japan
http://www.biosimilarnews.com, , 24-Jul-2017
Merck receives tentative approval for LUSDUNA Nexvue (insulin glargine injection) from FDA
http://www.biosimilarnews.com, , 24-Jul-2017
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Medline, Arthritis research & therapy [19] 168, 23-Jul-2017
Biosimilars in Oncology in the United States: A Review.
Medline, JAMA oncology, 22-Jul-2017
Showing Records 0 ... 20  

The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts


Name: Biosimilar (Tag)
Type: Technology



Must Mention A:

In Context:


Show Most Frequent

Optional, Only Include Source:


[Not available (Why?)]